Key Moments
I Did Mushrooms for Science, Pt. 2
Bryan JohnsonKey Moments
Taking a 'heroic dose' of psilocybin reset Bryan Johnson's biology, lowering blood sugar by 8% and inflammation to undetectable levels, suggesting it could be a longevity therapy.
Key Insights
Bryan Johnson's psilocybin experiment involved 249 biomarkers, including brain activity, inflammation, hormones, metabolism, and cellular aging, making it the most quantified psychedelic study to date.
After a 'heroic dose' of 4.67g of psilocybin, Bryan Johnson experienced a 42% drop in morning cortisol and a 45% drop in DHEA five days later, indicative of a measurable biochemical state of rest known as the 'afterglow'.
Brain scans revealed increased entropy and flexibility, with reduced activity in the Default Mode Network and enhanced communication between sensory, auditory, and language regions, suggesting a reset to a more youthful brain state.
Following two psilocybin doses, Bryan Johnson's average blood sugar dropped by 8%, variability by 11%, and time above 125 mg/dL went to zero, improving his estimated HbA1c from 4.7 to 4.4, placing him in the top 0.2% of healthy individuals.
Inflammation markers (hs-CRP) dropped below detectable limits (from 0.23 to 0.15) after the first dose and remained suppressed after the second, a significant finding given chronic inflammation's role in accelerating aging.
The experiment provided the first documented human evidence of improved blood sugar control via psilocybin and the first thermal imaging of an intense psilocybin experience.
The initial skepticism and scientific curiosity driving a novel experiment
Bryan Johnson, known for his meticulous approach to longevity and control, initially harbored reservations about psychedelics due to their subjective nature, which seemed antithetical to his data-driven methodology. However, a study indicating psilocybin's ability to extend the lifespan of human cells in vitro piqued his scientific interest. This, combined with emerging research on psilocybin as a therapy for mental health issues like depression and anxiety, created a compelling tension. While his 'Blueprint' project emphasized discipline and control, psilocybin temporarily overrides these very faculties. This led him to share his thoughts on social media, sparking a significant public response that encouraged him and his team to conduct a comprehensive scientific investigation. The objective was not merely to experience the drug but to uncover objective truths, leading to the design of what is described as the most quantified psychedelic experiment in history, measuring 249 biomarkers.
Navigating the psychological risks and the paradox of control
The decision to proceed with a 'heroic dose' of psilocybin, specifically 4.67 grams with 24.98 mg of psilocybin, was fraught with significant psychological apprehension. Johnson acknowledged the potential for profound shifts in his sense of self, values, and motivation, a concern amplified by anecdotes of individuals whose lives and projects were derailed after similar experiences. He recognized the cultural stigma surrounding psychedelics, often associated with chaos and loss of control, which contrasted sharply with his life's work. This created a paradox: pursuing longevity might require embracing the unknown and questioning his established beliefs, even if it meant risking his mission and identity. The fear was not of the substance itself, but of what it might reveal about his own identity and the potential loss of his current trajectory. Ultimately, he framed it as a researcher's question: 'Is the journey worth it?', necessitating a willingness to accept potentially disruptive outcomes.
The first dose: immediate effects and the 'afterglow' phenomenon
The initial dose was taken under carefully controlled conditions, emphasizing a calm and well-rested state. Johnson ingested 4.67 grams of dried B+ strain psilocybin. Subjectively, he described an experience characterized by openness, connection, and a childlike wonder, rather than the anticipated chaos. He reported feeling aligned and coherent, experiencing a smoothing of emotional turmoil. Biologically, the data revealed a notable 'afterglow' effect. While cortisol levels initially spiked, they returned to baseline by evening. Crucially, five days later, his morning cortisol levels dropped by 42%, and DHEA (a marker of adrenal activity) decreased by 45%. This measurable biochemical state of rest, indicating reduced stress programming and system recovery, aligned with his subjective feelings of calmness and emotional stability. This provided early data suggesting psilocybin's potential to reset stress response mechanisms.
Neurobiological changes: increased entropy and cognitive flexibility
Brain imaging using the Kernel Flow device, developed by Johnson himself, provided insights into the neurobiological impact. The experiment observed a quieting of the Default Mode Network (DMN), often associated with self-referential thought and the sense of 'self'. In this reduced DMN activity, communication between previously segregated brain regions—sensory, auditory, and language areas—increased. This phenomenon, known as increased entropy, signifies greater neural flexibility, curiosity, and a more youthful brain-like state. Johnson described this as a 'factory reset' of perception, dissolving the mental 'bluntness' associated with aging and restoring a sense of hyper-awareness and vividness. The data corroborated his subjective experience, showing a shift from rigid, decades-old neural patterns to a more dynamic and interconnected state, suggesting a potential reversal of age-related cognitive decline.
The second dose: escalating the experiment and public transparency
Building on the promising results from the first dose, a second, higher dose of 5.35 grams of psilocybin was administered three weeks later, with an expanded measurement profile including thermal imaging and continuous brain scans. This time, the experiment was conducted publicly via live stream. Johnson defended this transparency, arguing that rigorous testing of psychedelics is necessary to bring them back into mainstream scientific consideration. The public nature of the experiment, while drawing criticism for perceived recklessness, was intended to underscore the seriousness of the scientific inquiry. Family and friends joined virtually, adding an emotional and potentially biological layer to the experience. The cumulative effects were expected, but the focus remained on objective measurement and uncovering novel insights.
Metabolic Reset: Dramatic improvements in blood sugar control
One of the most unexpected and significant findings emerged from continuous glucose monitoring. Comparing three days before and after the first dose, Johnson's average blood sugar dropped by 8%, variability decreased by 11%, and time spent above 125 mg/dL was eliminated. This resulted in an estimated HbA1c reduction from 4.7 to 4.4, shifting his metabolic health from the top 2% to the top 0.2% of healthy young adults. This effect, achieved after a single neuroplastic event, is unprecedented and suggests psilocybin may trigger a reset in liver and pancreatic function, potentially mimicking or surpassing the efficacy of medications like metformin. This marked the first documented instance of psilocybin-induced improvement in blood sugar control in humans, offering a paradigm-shifting insight into its therapeutic potential for metabolic disorders.
Inflammation reduction and hormonal recalibration
Further data revealed a dramatic reduction in inflammation. His hs-CRP levels, a marker for underlying stress and damage, which were already low at 0.23, dropped below detectable limits to 0.15 after the first dose and remained suppressed. Given that chronic inflammation is a key driver of biological aging and linked to numerous diseases, this near-elimination of inflammation is a critical finding. Hormonally, the initial 'afterglow' effects on cortisol and DHEA were not isolated incidents. These patterns repeated after the second dose, indicating a measurable and persistent change in how his body manages stress at rest. This hormonal recalibration, combined with the reduction in inflammation, suggests a significant impact on core aging processes.
Cumulative biological system integration and implications for longevity
The data from both doses indicated a systemic effect, extending beyond individual biomarkers. Brain scans showed cumulative increases in entropy and integration three weeks after the second dose. The gut microbiome also shifted, with a decrease in species linked to stress and insulin resistance and the emergence of a new, beneficial species. Johnson identified stress, hormonal dysregulation, metabolic dysfunction, and chronic inflammation as the primary drivers of biological aging. His experiment demonstrated measurable improvements across all four of these core systems after just two quantified psilocybin doses, even in an already optimized body. This convergence of improvements across multiple biological systems, from the brain to metabolism and inflammation, strongly suggests that psilocybin could be a potent longevity therapy, not by altering perception, but by measurably influencing the biological processes that govern aging. The experiment generated two unprecedented human observations: continuous glucose monitoring showing improved blood sugar control and the first thermal imaging of an intense psilocybin experience. Johnson concluded that while further replication and study are necessary, psilocybin has earned a place in the longevity discussion, not as a replacement for foundational health practices, but as a tool that can profoundly influence biological aging processes.
Mentioned in This Episode
●Supplements
●Products
●Drugs & Medications
●Concepts
●People Referenced
Physiological Changes Post-Psilocybin Doses
Data extracted from this episode
| Metric | First Dose (4.67g) | Second Dose (5.35g) | Notes |
|---|---|---|---|
| Cortisol (Morning) | 42% decrease (5 days later) | Repeated measurable decrease | Part of 'Afterglow' effect |
| DHEA | 45% decrease | Repeated measurable decrease | Part of 'Afterglow' effect |
| Blood Glucose (Average) | 8% decrease | N/A (Monitored continuously) | Improved control, significant reduction in variability |
| Blood Glucose Variability | 11% decrease | N/A (Monitored continuously) | Improved control, significant reduction in variability |
| HbA1c (Estimated) | 4.7 to 4.4 (6.8% relative reduction) | N/A | Shifted from top 2% to top 0.2% of population |
| Inflammation (hs-CRP) | Below detection limit (0.15) | Remained suppressed | Chronically low baseline (0.23) further reduced |
| Brain Activity | Increased entropy, DMN quieted | Cumulative entropy and deeper integration | More flexible, curious, childlike brain patterns |
| Core Body Temperature | N/A | 0.8-1.1°C increase | Internal heat shift, indicating autonomic activation |
Common Questions
Psilocybin is a psychedelic compound found in 'magic mushrooms'. It's considered powerful due to its profound effects on perception, self-image, and the human mind, offering potential therapeutic benefits but also carrying risks of challenging experiences.
Topics
Mentioned in this video
Bryan Johnson's project focused on longevity and biological optimization through strict protocols.
A network of brain regions active during self-referential thought, which became quiet during the psilocybin experience.
A marker for inflammation in the body, which significantly decreased after psilocybin doses.
The name of Bryan Johnson's mission focused on preventing death and extending healthy human lifespan.
More from Bryan Johnson
View all 45 summaries
16 min8 Steps to Reclaim Your Life
23 minHow Bad Is Taco Bell REALLY?
26 minI Tried Psilocybin for Science (Livestream Highlights)
51 minSo I Tried Ketamine… | Bryan Johnson Podcast
Ask anything from this episode.
Save it, chat with it, and connect it to Claude or ChatGPT. Get cited answers from the actual content — and build your own knowledge base of every podcast and video you care about.
Get Started Free